EDAP TMS S.A. (EDAP) is a stock worth watching after climbing to its 52-week high on the back of record preliminary fourth-quarter and full-year 2025 results. Driven by strong demand for its Focal One High Intensity Focused Ultrasound (HIFU) system, the company posted its highest-ever HIFU revenue and continues to expand adoption across hospitals and urology centers. Backed by FDA clearance for advanced imaging upgrades and solid 2026 revenue guidance, EDAP is strengthening its role as a key innovator in minimally invasive prostate cancer therapy.
Company Overview
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.